Advertisement

Adverse events in patients with ulcerative colitis treated with indigo naturalis: a Japanese nationwide survey

  • Makoto NaganumaEmail author
  • Shinya Sugimoto
  • Hideo Suzuki
  • Yuichi Matsuno
  • Toshimitsu Araki
  • Hirotaka Shimizu
  • Ryohei Hayashi
  • Tomohiro Fukuda
  • Nobuhiro Nakamoto
  • Hideki Iijima
  • Shiro Nakamura
  • Masaharu Kataoka
  • Yuichi Tamura
  • Koichiro Tatsumi
  • Toshifumi Hibi
  • Yasuo Suzuki
  • Takanori KanaiEmail author
  • INDIGO survey Group
Original Article—Alimentary Tract

Abstract

Background

Although indigo naturalis (IN) is effective for patients with active ulcerative colitis (UC), IN was associated with adverse events (AEs), including pulmonary arterial hypertension (PAH). Our aim was to evaluate the occurrence of IN-associated AEs and to evaluate any IN dose–effect on AEs.

Methods

A nationwide survey, using questionnaires, was conducted by conducted by the research group funded by the Ministry of Health, Labour and Welfare of Japan, between June 2017 and September 2018. A first questionnaire determined the occurrence of AEs associated with the therapeutic use of IN or herbal medicines containing IN in patients with UC. A second survey identified the clinical characteristics of patients who developed IN-associated critical AEs, namely, liver dysfunction, PAH, and intussusception.

Results

Across 337 participating institutions, 49,320 patients with UC were identified, with IN used in 877 (1.8%). AEs were reported in 91 patients (107 events), including liver dysfunction (n = 40), gastrointestinal symptoms (n = 21), headache (n = 13), and PAH (n = 11). No dose–effect relationship between IN and AEs was identified. Liver dysfunction tended to be mild and reversible. Ten cases of intussusception were reported, with 40% of these patients requiring surgical resection. IN-induced PAH was recovered in patients who discontinued to use IN. No IN-associated deaths were reported.

Conclusions

IN-associated AEs were identified among patients with UC, with liver dysfunction often being reversible, while surgical resection was required in a high proportion of patients who developed intussusception. Both healthcare workers and patients should adequately recognize the potential for AEs with the use of IN.

Keywords

Ulcerative colitis Indigo naturalis Liver dysfunction Pulmonary arterial hypertension Intussusception 

Abbreviations

AE

Adverse event

ALP

Alkaline phosphatase

ALT

Alanine transaminase

AST

Aspartate transaminase

γ-GTP

γ-Glutamyl transpeptidase

IN

Indigo naturalis

PAH

Pulmonary arterial hypertension

UC

Ulcerative colitis

Notes

Acknowledgements

We thank all the collaborators who cooperated in this first nationwide survey of IN-induced adverse events in Japan. INDIGO survey Group are Makoto Naganuma, Shinya Sugimoto, Tomohiro Fukuda, Yusuke Yoshimatsu, Po-sung Chu, Nobuhiro Nakamoto, Masaharu Kataoka, Takanori Kanai (Keio University School of Medicine), Toshifumi Hibi (Kitasato Institute Hospital), Hideki Iijima (Osaka University Graduate School of Medicine), Motoi Uchino, Kenji Watanabe, Shiro Nakamura (Hyogo College of Medicine), Yasuo Suzuki (Toho University Sakura Medical Center), Yuichi Matsuno, Atsushi Hirano, Motohiro Esaki (Kyushu University), Ryohei Hayashi, Yoshitaka Ueno (Hiroshima University), Takayuki Yamamoto (Yokkaichi Hazu Medical Center), Koji Sawada (Dojima General and Gastroenterology Clinic), Kosaku Kawashima, Shunji Ishihara (Shimane University), Toshimitsu Araki (Mie University), Shinichi Hashimoto (Yamaguchi University), Junji Yokoyama (Niigata University), Shinya Ashizuka (University of Miyazaki), Hideo Suzuki (Tsukuba University), Tatsuya Toyokawa (Fukuyama Medical Center), Hirotake Sakuraba (Hirosaki University), Kazuhiro Matsueda (Kurashiki Central Hospital), Naoki Yoshimura (Yamate Medical Center), Naoki Ohmiya (Fujita Health University School of Medicine), Yoshiyuki Kayashima (Matsuyama Red Cross Hospital), Shunichi Yanai, Takayuki Matsumoto (Iwate Medical University), Hiroyuki Kobayashi (Fukuoka Sanno Hospital), Sachiko Nakajima, Tsutomu Nishida (Toyonaka Municipal Hospital), Yoshiaki Takeuchi (Showa University), Hirotaka Shimizu (National Center for Child Health and Development), Kenji Ina (Nagoya Memorial Hospital), Takuji Kawamura (Japanese Red Cross Kyoto Daini Hospital).

Author contributions

TK conceived the study. MN designed the main concept of this study and drafted the main protocol. SS and NN helped to draft the main protocol. MN and SS participated in analysis and interpretation of data. All the authors participated in patient enrolment and clinical data acquisition. MN, SS and TK drafted and wrote the manuscript. All the authors contributed to critical review and approved the final draft.

Funding

This study was supported in part by Research Grants for special research on intractable diseases from the Ministry of Health, Labor and Welfare of Japan.

Compliance with ethical standards

Conflict of interest

MN received commercial research funds from EA pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd., outside the submitted work. SN received lecture fees from Mitsubishi Tanabe Pharma Corp., AbbVie GK, Zeria Pharmaceutical co., Ltd., EA pharma Co., Ltd., and commercial research funds from Mitsubishi Tanabe Pharma Corp., AbbVie GK, EA pharma Co., Ltd., Kyorin Pharmaceutical Co., Ltd, JIMRO Co., Ltd., Otsuka Pharmaceutical Factory Inc., Takeda Pharmaceutical Co., Ltd, outside the submitted work. YS received lecture fees from Mitsubishi Tanabe Pharma Corp., AbbVie GK, Zeria Pharmaceutical co., Ltd., EA pharma Co., Ltd., Kyorin Pharmaceutical Co., Ltd. Janssen Japan Co., Ltd and commercial research funds from Mitsubishi Tanabe Pharma Corp., EA pharma Co., Ltd., AbbVie GK, EA pharma Co., Ltd., Kyorin Pharmaceutical Co., Ltd, AbbVie GK, JIMRO Co., Ltd., outside the submitted work. TK received lecture fees from Mitsubishi Tanabe Pharma Corp, Astellas Pharma Inc, Miyarisan Pharmaceutical Co., Ltd. AstraZeneca Plc, EA Pharma Co., Ltd., Kyorin Pharmaceutical Co., Ltd. and commercial research funds from AbbVie GK, Mochida Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corp, Takeda Pharmaceutical Co., Ltd., Nihon Kayaku, Yakult Honsha Co., Ltd., Zeria Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., Ezaki Glico Co., Ltd. JIMRO Co., Ltd., EN Otsuka Pharmaceutical Co., Ltd, outside the submitted work.

References

  1. 1.
    Sugimoto S, Naganuma M, Kanai T. Indole compounds may be promising medicines for ulcerative colitis. J Gastroenterol. 2016;51:853–61.CrossRefGoogle Scholar
  2. 2.
    Naganuma M, Sugimoto S, Mitsuyama K, et al. Efficacy of indigo naturalis in a multicenter randomized controlled trial of patients with ulcerative colitis. Gastroenterology. 2018;154:935–47.CrossRefGoogle Scholar
  3. 3.
    Nishio M, Hirooka K, Doi Y. Chinese herbal drug natural indigo may cause pulmonary artery hypertension. Eur Heart J. 2016;37:1992.CrossRefGoogle Scholar
  4. 4.
    Sugimoto S, Naganuma M, Kiyohara H, et al. Clinical efficacy and safety of oral Qing-Dai in patients with ulcerative colitis: a single-center open-label prospective study. Digestion. 2016;93:193–201.CrossRefGoogle Scholar
  5. 5.
    Kondo S, Araki T, Okita Y, et al. Colitis with wall thickening and edematous changes during oral administration of the powdered form of Qing-dai in patients with ulcerative colitis: a report of two cases. Clin J Gastroenterol. 2018;11:268–72.CrossRefGoogle Scholar
  6. 6.
    Yanai S, Nakamura S, Matsumoto T. Indigo naturalis-induced colitis. Dig Endosc. 2018;30:791.CrossRefGoogle Scholar
  7. 7.
    Zhang ZM, Lin XC, Ma L, et al. Ischemic or toxic injury: a challenging diagnosis and treatment of drug-induced stenosis of the sigmoid colon. World J Gastroenterol. 2017;23:3934–44.CrossRefGoogle Scholar
  8. 8.
    Matsuno Y, Hirano A, Esaki M. Possible association of phlebitis-induced colitis with indigo naturalis. Gastroenterology. 2018;155:576–7.CrossRefGoogle Scholar
  9. 9.
    Marinis A, Yiallourou A, Samanides L, et al. Intussusception of the bowel in adults: a review. World J Gastroenterol. 2009;15:407–11.CrossRefGoogle Scholar
  10. 10.
    Begos DG, Sandor A, Modlin IM. The diagnosis and management of adult intussusception. Am J Surg. 1997;173:88–94.CrossRefGoogle Scholar
  11. 11.
    Choi YS, Suh JP, Lee IT, et al. Regression of giant pseudopolyps in inflammatory bowel disease. J Crohns Colitis. 2012;6:240–3.CrossRefGoogle Scholar
  12. 12.
    Esaki M, Matsumoto T, Fuyuno Y, et al. Giant inflammatory polyposis of the cecum with repeated intussusception in ulcerative colitis: report of a case. Am J Gastroenterol. 2009;104:2873–4.CrossRefGoogle Scholar
  13. 13.
    Maldonado TS, Firoozi B, Stone D, et al. Colocolonic intussusception of a giant pseudopolyp in a patient with ulcerative colitis: a case report and review of the literature. Inflamm Bowel Dis. 2004;10:41–4.CrossRefGoogle Scholar
  14. 14.
    Takeuchi K, Tsuzuki Y, Ando T, et al. The diagnosis and treatment of adult intussusception. J Clin Gastroenterol. 2003;36:18–211.CrossRefGoogle Scholar
  15. 15.
    Nishio M, Hirooka K, Doi Y. Pulmonary arterial hypertension associated with the Chinese herb indigo naturalis for ulcerative colitis: it may be reversible. Gastroenterology. 2018;155:577–8.CrossRefGoogle Scholar
  16. 16.
    Lin YK, See LC, Huang YH, et al. Comparison of indirubin concentrations in indigo naturalis ointment for psoriasis treatment: a randomized, double-blind, dosage-controlled trial. Br J Dermatol. 2018;178:124–31.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Gastroenterology 2019

Authors and Affiliations

  • Makoto Naganuma
    • 1
    Email author
  • Shinya Sugimoto
    • 1
  • Hideo Suzuki
    • 2
  • Yuichi Matsuno
    • 3
  • Toshimitsu Araki
    • 4
  • Hirotaka Shimizu
    • 5
  • Ryohei Hayashi
    • 6
  • Tomohiro Fukuda
    • 1
  • Nobuhiro Nakamoto
    • 1
  • Hideki Iijima
    • 7
  • Shiro Nakamura
    • 8
  • Masaharu Kataoka
    • 9
  • Yuichi Tamura
    • 10
  • Koichiro Tatsumi
    • 11
  • Toshifumi Hibi
    • 12
  • Yasuo Suzuki
    • 13
  • Takanori Kanai
    • 1
    Email author
  • INDIGO survey Group
  1. 1.Division of Gastroenterology and Hepatology, Department of Internal MedicineKeio University School of MedicineTokyoJapan
  2. 2.Department of Gastroenterology, Institute of Clinical MedicineUniversity of Tsukuba Graduate SchoolIbarakiJapan
  3. 3.Department of Medicine and Clinical Science, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan
  4. 4.Department of Gastrointestinal and Pediatric SurgeryMie University Graduate School of MedicineTsuJapan
  5. 5.Division of GastroenterologyNational Center for Child Health and DevelopmentTokyoJapan
  6. 6.Department of EndoscopyHiroshima University HospitalHiroshimaJapan
  7. 7.Department of Gastroenterology and HepatologyOsaka University Graduate School of MedicineOsakaJapan
  8. 8.Department of Intestinal Inflammation ResearchHyogo College of MedicineNishinomiyaJapan
  9. 9.Division of Cardiology, Department of Internal MedicineKeio University School of MedicineTokyoJapan
  10. 10.Pulmonary Hypertension CenterInternational University of Health and Welfare Mita HospitalTokyoJapan
  11. 11.Department of Respirology, Graduate School of MedicineChiba UniversityChibaJapan
  12. 12.Center for Advanced IBD Research and TreatmentKitasato University Kitasato Institute HospitalTokyoJapan
  13. 13.IBD CenterToho University Sakura Medical CenterSakuraJapan

Personalised recommendations